PRESSRELEASES

6 May, 2021

Interim report Q1 2021

“The development of Nanexa is continuing and at the beginning of the quarter we started our second proprietary product project, NEX-20. The choice of multiple myeloma as our second indication fits well with myelodysplastic syndrome (MDS) in NEX-18 and creates an interesting portfolio in haematological cancer. In 2021, we intend to identify another project, NEX-21, where PharmaShell® can create another unique product with major potential.” David Westberg, CEO Nanexa AB.

28 April, 2021

Nanexa launches clinical trial for NEX-18

Nanexa AB (publ) today announces that the company has started its first clinical study with PharmaShell®, a phase I study in Nanexa’s product project NEX-18, at the Karolinska University Hospital.

CURRENT

14 april, 2021

Aktiekvällen Stockholm, Aktiespararna



8 februari, 2021

Webcast och frågestund

NEWSLETTER

Meet Nanexa